IGC Pharma, Inc., a company incorporated in Maryland, has filed its annual report (Form 10-K) for the fiscal year ended March 31, 2024. The report includes detailed information about the company's operations, financial condition, and performance over the fiscal year.
Market Value and Shareholders: As of September 30, 2023, the last business day of the company's second fiscal quarter, the aggregate market value of the voting and non-voting stock held by non-affiliates was approximately $20,882,737. There were 75,636,419 shares of common stock outstanding as of June 18, 2024.
Financial Performance and Compliance: The company has disclosed that it has filed all required reports for the preceding 12 months and has been subject to these reporting requirements for the past 90 days. It has also indicated compliance with the requirements for electronic filing of interactive data files and has classified itself as a non-accelerated filer.
Regulatory Compliance: IGC Pharma has indicated that it is not required to include an attestation to its management assessment of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, as the company has not engaged a registered public accounting firm to perform this assessment. The company has not corrected any errors to previously issued financial statements nor has it undergone a recovery analysis of incentive-based compensation received by executive officers.
Stock Listing and Legal Proceedings: The company's common stock is listed on the NYSE American LLC exchange. No legal proceedings are currently mentioned in the report. The company has not declared any dividends in the last two years.
Market for Common Equity: The aggregate market value of the common stock held by non-affiliates reflects the company's market standing. The stock listing status suggests the company maintains a certain level of transparency and liquidity in the market.
Future Outlook: The report includes a cautionary note regarding forward-looking statements, highlighting the potential for differences between actual outcomes and projected results due to various risks and uncertainties. These include market demand, economic conditions, regulatory approvals, competitive pressures, and technological advancements.
This summary provides an overview of the key points covered in the annual report without delving into specific details or analysis that would require a comprehensive review of the full document.
